cbdMD Applauds White House Initiative for Equitable Hemp Regulations
cbdMD, Inc., a prominent player in the hemp-derived wellness sector, has expressed its strong approval of the recent White House initiative advocating for fair treatment of hemp-derived products within the federal legislative framework. This move comes as federal efforts continue to reshape the legal landscape for hemp, significantly influencing how these products are regulated and perceived in the market.
As an established company publicly traded under NYSE American as YCBD, cbdMD is well-positioned in the evolving cannabinoid industry, where significant changes are anticipated. In a letter directed towards congressional leaders, the White House Office of Management and Budget emphasized the urgency of reforming hemp regulations. This proposal aims to ensure equitable treatment of hemp-derived products while keeping consumer safety as a top priority. The Administration's call to Congress includes preserving access to full-spectrum CBD products, crucial for many consumers, while still addressing concerns regarding health risks associated with certain products.
Ronan Kennedy, the CEO of cbdMD, stated, "It’s heartening to see the Administration taking a clear stance for responsibly produced hemp products that consumers rely on daily." cbdMD is committed to the principles of quality and transparency which they believe are essential in distinguishing responsible operators from those only seeking profit without concern for safety. In alignment with their vision, cbdMD advocates for a federal framework that encourages safety, provides clear guidelines, and ultimately delivers assurance to compliant companies and consumers alike.
Moreover, the conversation around federal cannabis policy has garnered considerable attention from investors, researchers, and industry insiders. The willingness of major U.S. exchanges to list compliant cannabis operators further underscores a trend toward legitimacy and transparency in the cannabinoid marketplace. While this federal cannabis reclassification differs from hemp product matters, the ongoing policy changes highlight a broader acceptance and maturation within the industry.
As cbdMD continues to navigate these changes, they remain focused on delivering trustworthy, effective products to their customers while supporting responsible regulations. Kennedy added that "cbdMD is well-prepared for whatever the next stage in the market brings." Their commitment to evaluating emerging opportunities in the evolving landscape ensures that they not only adapt but thrive as regulations develop.
Founded in Charlotte, North Carolina, cbdMD operates with a diverse range of hemp-derived wellness brands, making it a recognized name in both the industry and among consumers. Their product range emphasizes quality and transparency, vital components as the nation grapples with hemp’s regulatory restructuring. To this end, cbdMD's proactive engagement in advocacy ensures they're not just participants in the market but leaders pushing for progress in regulatory reforms that align with consumer safety and industry best practices.
In summary, cbdMD’s support for the White House’s push toward equitable treatment of hemp products signals a positive shift in how hemp-derived wellness products may be treated moving forward. Along with paving the way for enhanced consumer access and safety, this initiative reflects cbdMD's commitment to lead from the forefront in the cannabis and hemp-derived products industry.
As an established company publicly traded under NYSE American as YCBD, cbdMD is well-positioned in the evolving cannabinoid industry, where significant changes are anticipated. In a letter directed towards congressional leaders, the White House Office of Management and Budget emphasized the urgency of reforming hemp regulations. This proposal aims to ensure equitable treatment of hemp-derived products while keeping consumer safety as a top priority. The Administration's call to Congress includes preserving access to full-spectrum CBD products, crucial for many consumers, while still addressing concerns regarding health risks associated with certain products.
Ronan Kennedy, the CEO of cbdMD, stated, "It’s heartening to see the Administration taking a clear stance for responsibly produced hemp products that consumers rely on daily." cbdMD is committed to the principles of quality and transparency which they believe are essential in distinguishing responsible operators from those only seeking profit without concern for safety. In alignment with their vision, cbdMD advocates for a federal framework that encourages safety, provides clear guidelines, and ultimately delivers assurance to compliant companies and consumers alike.
Moreover, the conversation around federal cannabis policy has garnered considerable attention from investors, researchers, and industry insiders. The willingness of major U.S. exchanges to list compliant cannabis operators further underscores a trend toward legitimacy and transparency in the cannabinoid marketplace. While this federal cannabis reclassification differs from hemp product matters, the ongoing policy changes highlight a broader acceptance and maturation within the industry.
As cbdMD continues to navigate these changes, they remain focused on delivering trustworthy, effective products to their customers while supporting responsible regulations. Kennedy added that "cbdMD is well-prepared for whatever the next stage in the market brings." Their commitment to evaluating emerging opportunities in the evolving landscape ensures that they not only adapt but thrive as regulations develop.
Founded in Charlotte, North Carolina, cbdMD operates with a diverse range of hemp-derived wellness brands, making it a recognized name in both the industry and among consumers. Their product range emphasizes quality and transparency, vital components as the nation grapples with hemp’s regulatory restructuring. To this end, cbdMD's proactive engagement in advocacy ensures they're not just participants in the market but leaders pushing for progress in regulatory reforms that align with consumer safety and industry best practices.
In summary, cbdMD’s support for the White House’s push toward equitable treatment of hemp products signals a positive shift in how hemp-derived wellness products may be treated moving forward. Along with paving the way for enhanced consumer access and safety, this initiative reflects cbdMD's commitment to lead from the forefront in the cannabis and hemp-derived products industry.
Topics Consumer Products & Retail）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.